Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC

Zhao,Mingchuan; Zhang,Yishi; Li,Jiayu; Li,Xuefei; Cheng,Ningning; Wang,Qi; Cai,Weijing; Zhao,Chao; He,Yayi; Chang,Jianhua; Zhou,Caicun

doi:10.3892/ol.2017.7411

Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC

Authors:
- Mingchuan Zhao
- Yishi Zhang
- Jiayu Li
- Xuefei Li
- Ningning Cheng
- Qi Wang
- Weijing Cai
- Chao Zhao
- Yayi He
- Jianhua Chang
- Caicun Zhou
View Affiliations

Affiliations: Department of Oncology, Fudan University Shanghai Cancer Center, Fudan University School of Medicine, Shanghai 200032, P.R. China, Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P.R. China
Published online on: November 14, 2017 https://doi.org/10.3892/ol.2017.7411
Pages: 1089-1096

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance remains a major challenge in epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI) therapy. Bcl‑2‑like protein 11 (BIM), a B‑cell lymphoma 2 family pro‑apoptotic protein, is a prime target for specific anti‑cancer therapeutics. However, the epigenetic regulation of BIM in non‑small cell lung cancer (NSCLC) cell lines and patients with NSCLC in association with EGFR‑TKI resistance requires investigation. Methylation‑specific PCR (MSP), pyrosequencing, and nested quantitative (q)‑MSP were conducted to explore the methylation status of BIM in NSCLC cell lines. In addition, the methylation profile of BIM in patients with NSCLC was assessed by nested q‑MSP using circulating free DNA. Cell lines, treated with methylation inhibitor 5‑Aza‑2'‑deoxycytidine (AZA) or histone deacetylation inhibitor trichostatin A (TSA) prior to gefitinib treatment, were examined for BIM gene expression and resistance to gefitinib. All cell lines used in the present study presented with hypo‑methylated BIM. Treatment with AZA had no effect on BIM RNA expression in PC9 cells or the gefitinib‑resistant cell lines PC9/R and PC9/G2, nor did it reverse their resistance to gefitinib. In contrast, TSA treatment produced the opposite result. In the present study, 25 (78.1%) patients with hypo‑methylated BIM and 7 patients (21.9%) with partial or hyper‑methylated BIM were identified. The clinicopathological data revealed a random hypo‑methylated BIM distribution amongst patients with NSCLC. In the overall study group and EGFR mutant group, hypo‑methylated BIM carriers presented with no significant differences in progression free survival compared with patients with partial or hyper‑methylated BIM. All cell lines in the present study and the majority of patients with NSCLC carried hypo‑methylated BIM. Histone deacetylation, as opposed to promoter methylation, may contribute to the epigenetic silencing of BIM and lead to EGFR TKI resistance in NSCLC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
4	Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D and Soria JC: Erlotinib for frontline treatment of advanced non-small cell lung cancer: A phase II study. Clin Cancer Res. 12:6049–6055. 2006. View Article : Google Scholar : PubMed/NCBI
5	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
7	Nakazawa Y, Saha S, Galvan DL, Huye L, Rollins L, Rooney CM and Wilson MH: Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother. 36:3–10. 2013. View Article : Google Scholar : PubMed/NCBI
8	Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH and Miller VA: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 13:5150–5155. 2007. View Article : Google Scholar : PubMed/NCBI
9	Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, et al: A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 18:521–528. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N, Ren R, Zhao C, Li X, Ren S, et al: The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 120:2299–2307. 2014. View Article : Google Scholar : PubMed/NCBI
11	O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S and Huang DC: Bim: A novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17:384–395. 1998. View Article : Google Scholar : PubMed/NCBI
12	San José-Eneriz E, Agirre X, Jiménez-Velasco A, Cordeu L, Martín V, Arqueros V, Gárate L, Fresquet V, Cervantes F, Martínez-Climent JA, et al: Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 45:1877–1889. 2009. View Article : Google Scholar : PubMed/NCBI
13	Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, et al: Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood. 116:2531–2542. 2010. View Article : Google Scholar : PubMed/NCBI
14	Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, et al: Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. Neoplasia. 15:511–522. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S, Hartmann C, Fritsch RM, Gillissen B, Daniel PT and Häcker G: Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: Evidence for contribution to apoptosis resistance. Oncogene. 26:7038–7048. 2007. View Article : Google Scholar : PubMed/NCBI
16	Singal R and Ginder GD: DNA methylation. Blood. 93:4059–4070. 1999.PubMed/NCBI
17	Fuks F, Burgers WA, Brehm A, Hughes-Davies L and Kouzarides T: DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 24:88–91. 2000. View Article : Google Scholar : PubMed/NCBI
18	Ju L, Zhou C, Li W and Yan L: Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem. 111:1565–1574. 2010. View Article : Google Scholar : PubMed/NCBI
19	Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, et al: MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer. 83:146–153. 2014. View Article : Google Scholar : PubMed/NCBI
20	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
21	Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, et al: DNA methylation profiles of lung tumors. Mol Cancer Ther. 1:61–67. 2001.PubMed/NCBI
22	Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF and Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61:249–255. 2001.PubMed/NCBI
23	Wilting RH and Dannenberg JH: Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 15:21–38. 2012. View Article : Google Scholar : PubMed/NCBI
24	Yang Y, Takeuchi S, Hofmann WK, Ikezoe T, van Dongen JJ, Szczepański T, Bartram CR, Yoshino N, Taguchi H and Koeffler HP: Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk Res. 30:98–102. 2006. View Article : Google Scholar : PubMed/NCBI
25	Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H and Tanimoto M: Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 11:1219–1257. 2005.PubMed/NCBI
26	Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y and Yano S: EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 73:2428–2434. 2013. View Article : Google Scholar : PubMed/NCBI
27	Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA Jr and Hirsch FR: Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 30:2248–2255. 2012. View Article : Google Scholar : PubMed/NCBI
28	Capobianco E, Mora A, La Sala D, Roberti A, Zaki N, Badidi E, Taranta M and Cinti C: Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One. 9:e955962014. View Article : Google Scholar : PubMed/NCBI
29	Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
30	Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C and Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 46:318–322. 1989. View Article : Google Scholar : PubMed/NCBI
31	Nawroz H, Koch W, Anker P, Stroun M and Sidransky D: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 2:1035–1037. 1996. View Article : Google Scholar : PubMed/NCBI
32	Mulcahy HE, Lyautey J, Lederrey C, qi Chen X, Anker P, Alstead EM, Ballinger A, Farthing MJ and Stroun M: A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res. 4:271–275. 1998.PubMed/NCBI
33	Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL and Cairns P: Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients. Cancer Res. 64:6476–6481. 2004. View Article : Google Scholar : PubMed/NCBI
34	Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK, Lee HC and Wang YC: Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer. 110:2019–2026. 2007. View Article : Google Scholar : PubMed/NCBI